Immix Biopharma Inc. (NASDAQ: IMMX) was up 30% after the biopharmaceutical firm pioneering Tissue-Specific Therapeutics targeting immune-dysregulated and oncology diseases announced positive preliminary trial data showing that after one treatment cycle, its lead candidate IMX-110 had 75% survival compared to 0% survival for FDA-approved drug Trabectedin that is sold as YONDELIS.
Trading Data
On Friday, IMMX stock gained 30.06% to $2.12 with more than 111.65 million shares, compared to its average volume of 2 million shares. The stock moved within a range of $2.0700 – 2.8700 after opening trade at $2.49.
Key Details
The company compared IMX-110 against approved drugs from STS treatment in the study. IMX-110 was given at 2.0 mg/kg while Trabectedin was administered as per Meco et al. (2003) monotherapy arm.
See Why This OTC Fintech Stock May Have Investors Seeing Green
CEO of ImmixBio Ilya Rachman said that they are delighted to see ongoing evidence of IMX-110 antitumor activity compared to already approved therapies. He explained that the findings are a preview of IMX-110’s antitumor activity to be shown in the two clinical studies expected to commence in 2022. Then trials include IMX-110 monotherapy plus a combination of IMX-110 with anti-PD-1 tislelizumab. IMX-110 has been awarded orphan drug designation for soft tissue sarcoma and a rare pediatric disease designation for rhabdomyosarcoma treatment. So IMMX is worth watching.
Key Quote
“We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “We believe this is a preview of anti-tumor activity to be demonstrated in our 2 clinical trials to be kicked off in 2022: IMX-110 monotherapy, and IMX-110 in combination with anti-PD-1 tislelizumab.”
Technical Data
IMMX stock is trading above the 20-Day and 50-Day Moving averages of $1.54 and $1.80 respectively. However, the stock is trading below the 200-Day moving average of $3.03.
